Gynecological cancer
A selection of insight articles on the topic of gynecologic cancer biomarkers:
Biomarkers as effective tools for detecting ovarian cancer recurrence
The American Cancer Society has estimated that in 2021, about 21,410 women in the US will receive a new diagnosis of ovarian cancer (OC), and about 13...
Therapeutic strategies for ovarian cancer and the use of biomarkers for monitoring prognosis
Over the last decades, biomarkers have become an extremely important tool in the care of patients with ovarian cancer. Biomarkers are capable of...
An overview of ovarian cancer: the development of biomarkers for early detection
It has been estimated that in 2020, about 21,750 women in the US will receive a new ovarian cancer diagnosis and about 13,940 women will die from this...
Did you know? The discovery of the CA125 biomarker
CA125, also known as mucin 16 or MUC16 is a member of the mucin family glycoproteins. Based on early experience with immune therapy for cancer...
What is HE4 (Human Epididymis protein 4)?
Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of death from cancer in women.4...
